Multicenter Study
A phase 1/2a, dose-escalation, safety and preliminary efficacy study of oral therapeutic vaccine in subjects with cervical intraepithelial neoplasia 3.
J Gynecol Oncol. 2019 Nov 1; 30 (6): e88.
Randomized Controlled Trial
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
Lancet Oncol. 2012 Jan 1; 13 (1): 899989-99.
Randomized Controlled Trial
Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind,...
Lancet. 2015 Nov 21; 386 (10008): 2078-2088.